Y-mAbs Therapeutics (YMAB) Stock Analysis

What Y-mAbs Therapeutics does

Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-stimulating factor, targeting high-risk neuroblastoma in children when the disease has returned or proven resistant to prior treatments. Beyond its approved indication, DANYELZA is undergoing Phase II trials for new applications, including initial and third-line neuroblastoma, as well as relapsed osteosarcoma. Furthermore, Y-mAbs is progressing with a GD2-GD3 vaccine, currently in Phase II for aggressive Stage 4 neuroblastoma. Another key asset, Omburtamab, a murine monoclonal antibody, is being evaluated in clinical studies for a range of challenging conditions: central nervous system and leptomeningeal spread of neuroblastoma, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other cancers expressing the B7-H3 protein. The company's pipeline also features Nivatrotamab, which is being investigated for small cell lung cancer and is in Phase I/II trials for persistent GD2-positive solid tumors in both adult and pediatric populations. Completing its early-stage portfolio is Lu-omburtamab-DTPA, a Phase I candidate aimed at treating medulloblastoma and B7-H3 positive leptomeningeal metastases originating from solid tumors. Y-mAbs maintains a licensing arrangement with both the Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, enabling it to advance and market certain agreed-upon therapies. Established in 2015, Y-mAbs Therapeutics, Inc. operates from its headquarters in New York City.

Key metrics

ETFs linked to YMAB

Broad-market and Healthcare sector ETFs an investor holding Y-mAbs Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how YMAB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Y-mAbs Therapeutics?

Y-mAbs Therapeutics trades under the ticker YMAB on NASDAQ.

Which exchange is YMAB listed on?

YMAB is listed on NASDAQ.

What sector does Y-mAbs Therapeutics operate in?

Y-mAbs Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze YMAB in a portfolio?

PortView shows YMAB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.